High-dose administration of EGFR-TKIs for NSCLC patients: a literature review
Abstract
High-dose EGFR-TKIs have been used as an exploratory therapeutic strategy to overcome the limitations of the standard-dose regimen in the treatment of EGFR-mutant NSCLC, particularly in patients with CNS metastases. Available clinical evidence suggests that high-dose TKIs confer certain therapeutic efficacy and manageable safety profiles, with a small proportion of patients experiencing ≥3 grade adverse events, such as rash, nausea,diarrhea, aminotransferase rise, leukopenia.However, the evidence is limited by the predominance of single-center retrospective studies, small sample sizes, heterogeneous patient populations and short follow-up periods. Further large-scale, multicenter studies with long-term follow-up are needed to define more clearly the efficacy, safety, and appropriate clinical role of high-dose EGFR-TKI therapy.
Related
- Primary resistance to afatinib in a patient with NSCLC harboring EGFR p.E709_T710delinsD and brain metastases: a case report and literature review
- High Bleeding Risk Patients Undergoing Percutaneous Coronary Intervention: How to Choose the Optimal Antithrombotic Therapy, Its Duration and the Right Stent; A Comprehensive Review of the Current Literature and Proposed Treatment Algorithms
- Early clinical experience with a novel automated fecal management system for fecal incontinence in high-risk oncology and intensive care unit patients: a retrospective analysis and structured narrative literature review.
- Durvalumab completion and re-administration after grade 2 radiation pneumonitis following concurrent chemoradiotherapy for unresectable stage III NSCLC: a single-center real-world study
- High-Origin Visceral and Renal Arteries with a Symptomatic Right Renal Artery Aneurysm: A Case Report and Literature Review
BibTeX
@article{cheng2026highdose,
title = {{High-dose administration of EGFR-TKIs for NSCLC patients: a literature review}},
author = {Kai Cheng and Yan Chen and Xiaowen Tao and HongTao Xiao and Hua Xie},
journal = {Frontiers in Pharmacology},
year = {2026},
month = nov,
doi = {10.3389/fphar.2026.1903921},
url = {https://www.frontiersin.org/articles/10.3389/fphar.2026.1903921},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - High-dose administration of EGFR-TKIs for NSCLC patients: a literature review
AU - Kai Cheng
AU - Yan Chen
AU - Xiaowen Tao
AU - HongTao Xiao
AU - Hua Xie
PY - 2026
DA - 2026/11/09
JO - Frontiers in Pharmacology
DO - 10.3389/fphar.2026.1903921
UR - https://www.frontiersin.org/articles/10.3389/fphar.2026.1903921
AB - High-dose EGFR-TKIs have been used as an exploratory therapeutic strategy to overcome the limitations of the standard-dose regimen in the treatment of EGFR-mutant NSCLC, particularly in patients with CNS metastases. Available clinical evidence suggests that high-dose TKIs confer certain therapeutic efficacy and manageable safety profiles, with a small proportion of patients experiencing ≥3 grade adverse events, such as rash, nausea,diarrhea, aminotransferase rise, leukopenia.However, the evidence is limited by the predominance of single-center retrospective studies, small sample sizes, heterogeneous patient populations and short follow-up periods. Further large-scale, multicenter studies with long-term follow-up are needed to define more clearly the efficacy, safety, and appropriate clinical role of high-dose EGFR-TKI therapy.
SN - 1663-9812
ER -